VTRS
Viatris Inc.$14.91
Sell
Target $9.96
Report: Mar 07, 2026Healthcare • Drug Manufacturers - Specialty & Generic • Turnaround CandidateSnapshot
Decision-first overview with recommendation, valuation anchor, and current setup.
Company Overview
Research Snapshot
Price History
Pelican View
Current$14.91-33.2%
Rec: SellConviction: Low
Entry Target
N/A
N/A
Fair Value
$9.96
(33% below current)
Stop Loss
N/A
N/A
Position Size
None
Time Horizon
N/A
Key Metrics
Live Snapshot
Market Data
52 Week High$16.47
52 Week Low$6.85
Avg. 3 Month Volume10.24M
Efficiency
LTM Gross Margin35.1%
LTM EBITDA Margin-2.8%
LTM EBIT Margin-22.3%
LTM Operating Margin-18.6%
LTM ROA-9.2%
LTM ROE-23.0%
LTM ROIC-14.5%
LTM ROCE-10.0%
Capital Structure
Market Cap (MM)$15.6B
Enterprise Value (MM)$28.6B
Shares Outstanding1.15B
Total Debt (MM)$14.41B
Cash & Equivalents (MM)$1.32B
LTM Net Debt (MM)$13.09B
LTM Net Debt/EBITDA-33.1x
Growth
TTM Rev. Growth-3.0%
Last 3-Yr Rev. CAGR-4.2%
Last 3-Yr EBITDA CAGRN/A
Last 3-Yr EPS CAGRN/A
Valuation
Street Target Price$15.25
LTM EV/Revenue2.0x
LTM EV/Gross Profit5.7x
LTM EV/EBIT-9.0x
LTM EV/EBITDA-72.5x
LTM P/E-4.4x
LTM EV/FCF14.5x
LTM P/FCF7.9x
LTM P/TB1.0x
LTM P/B1.1x
Dividend Yield3.6%
Payout Ratio-16.2%
Executive SummarySituation: Current price is $14.91 versus fair value $9.96 (-33.2% expected return), and valuation confidence is stable. Debate: Bull case depends on Phased implementation of 650 million cost-saving plan. Bear case centers on Existential Liquidity and Solvency Risk. Conclusion: Recommendation is Sell with no position, pending a materially better risk/reward setup.
Bull Case
Management successfully executes the 650 million cost-saving plan and launches 500 million in new products, restoring operating margins to 12% by 2028. Free cash flow of 2.2 billion remains stable enough to continue debt repayment and dividends.
Bear Case
Margin erosion in the core generic business outpaces cost savings, and regulatory delays at the Indore and Nashik facilities lead to a covenant breach (3.75x leverage limit). The negative tangible book value of 7.1 billion provides no floor, leading to a total loss for equity holders.
Key Catalysts
Mid-Term (6-18 months)Impact: High
Phased implementation of 650 million cost-saving plan. If the first 30% of savings (expected in 2026) fails to materialize in the operating...
Near-Term (0-6 months)Impact: Critical
FDA Re-inspection of Indore Facility. A successful re-inspection would allow high-margin ARV products to return to the U.S. market, providin...
Long-Term (18+ months)Impact: Moderate
Viatris is at a critical juncture following its Q4 2025 earnings collapse and the announcement of a 10% workforce reduction. The market is c...
Primary Risks
Concern: High
Existential Liquidity and Solvency Risk. The company faces a 'race against time' to realize cost savings before its 14.4 billion debt load a...
Concern: High
Regulatory and Manufacturing Failure. Continued or expanded FDA import alerts at Indian facilities (Indore/Nashik) could permanently impair...
Concern: Medium
The governance structure is technically sound with high independence, but the stewardship of capital has been poor. The 'Governance Outcome...
Recent Activity
2026-02-26SEC Filing (8-K)
-5.16%Viatris reports Q4 2025 results, completes strategic review, and provides 2026 guidance.
2025-11-11SEC Filing (SC 13G/A)
+10.13%Davis Selected Advisers increased Viatris Inc holdings to 6.7% (69,345,645 shares) as of 9/30/2025
2025-11-06SEC Filing (8-K)
-5.95%Viatris reports Q3 2025 results and updates 2025 financial guidance.
2025-08-07SEC Filing (SC 13G/A)
+7.31%Davis Selected Advisers increased Viatris Inc holdings to 6.2% (66,375,520 shares) as of 6/30/2025
2025-05-08SEC Filing (SC 13G/A)
+5.70%Davis Selected Advisers held 6.0% (64,948,236 shares) of Viatris Inc as of 3/31/2025
Valuation Table
8.2/10Decision Grade